ClinicalTrials.gg
RecruitingNCT07446855PARTHENONUpdated Oct 27, 2026

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

A Phase 1/2 interventional study of AZD4956 and Saruparib in Solid Tumours, sponsored by AstraZeneca. Recruiting at 19 sites in 6 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 27, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Study summary

The purpose of this modular, first trial in human study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of ascending dose levels (DLs) of AZD4956 monotherapy and in combination with other anti-cancer agents in participants with advanced/metastatic solid tumours with homologous recombination repair (HRR) deficiencies.

Read the detailed description

The study consists of individual modules each evaluating the safety and tolerability of AZD4956 dosed as monotherapy, or with a specific combination partner. There are following 2 modules -

  1. Module 1: AZD4956 monotherapy
  2. Module 2: AZD4956 in combination with saruparib

Each module may further contain 2 parts-

  • Part A (dose escalation/dose finding): To determine the safety, tolerability, PK, PD, and preliminary efficacy of AZD4956 as monotherapy or in combination.
  • Part B (dose expansion): To further evaluate the safety and preliminary efficacy of AZD4956 in combination with other anti-cancer agents.
02

Conditions studied

  • Solid Tumours

Keywords

  • Advanced/metastatic homologous recombination repair defective solid tumours
  • Poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi)
  • Pharmacokinetics
  • Pharmacodynamics
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Core Inclusion Criteria:

  • Documented locally advanced or solid tumour .
  • (ECOG) performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to screening and first day of dosing.
  • Minimum ≥ 12 weeks.
  • Adequate organ and marrow function.
  • Female participants must not breastfeed and must not donate or retrieve ova for their own use from screening to approximately 6 months after the last dose of study intervention.

Module 1 Inclusion Criteria:

  • Demonstrated evidence of disease progression.
  • Participants must have advanced or metastatic solid tumours.
  • Participants may have received up to one with a poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi)-based regimen (either as a treatment or as maintenance).

Module 2 Inclusion Criteria:

Part A (AZD4956 in Combination with Saruparib Dose Escalation) and Part A-PD (PD Backfill Cohorts):

  • Participants must have one of the following conditions-

    1. or cytologically confirmed carcinoma of the breast with recurrent locally advanced or metastatic disease and evidence of a predicted loss of function germline or somatic mutation.
    2. Histologically or cytologically confirmed advanced ovarian, fallopian tube, or primary peritoneal cancer.
    3. Histologically or cytologically confirmed adenocarcinoma of the prostate and advanced/metastatic castrate resistant prostate cancer (CRPC).
    4. Histologically or cytologically confirmed advanced/metastatic pancreatic cancer.
  • Participants must have evaluable disease.
  • Participants in PD backfill cohorts must not have received prior therapy with a PARPi-based regimen (either as a treatment or as maintenance).

Part A (PD Backfill Cohorts) - Participants Undergoing Paired :

- Participants must have a tumour suitable for biopsy.

Part A-Non-PD (Non-PD Backfill Cohorts) and Part B (Dose Expansion Cohorts):

  • Participants must have histologically or cytologically confirmed adenocarcinoma of the prostate and advanced/metastatic CRPC.
  • Participants must have documented metastatic disease by clear evidence of ≥ 1 bone lesion (defined as one lesion with positive uptake on bone scan) and/or ≥ 1 soft tissue lesion (measurable or non-measurable).
  • Participants must have received the prior approved systemic therapies for metastatic prostate cancer.
  • Participants must not have received prior therapy with a PARPi-based regimen (either as a treatment or as maintenance).

Core Exclusion Criteria:

  • Any significant laboratory finding or any severe and uncontrolled medical condition.
  • Participants with any known predisposition to bleeding.
  • Spinal cord compression or symptomatic and unstable or .
  • Allogenic organ transplantation.
  • Known to have active infection, including virus (HBV) or virus (HCV).
  • Known history of infection with (HIV).
  • Active gastrointestinal disease or other condition that will interfere significantly with the swallowing, absorption, distribution, metabolism or excretion of oral therapy.
  • Participants with history of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) or with features suggestive of MDS/AML.
  • Participants with a known to the product(s) or any of the of the product(s).
  • Previous dosing with AZD4956.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Module 1 Part A: AZD4956 monotherapy (Dose escalation)

    Participants will receive AZD4956 as monotherapy at ascending dose levels.

    Drug: AZD4956

  • Experimental
    Module 2 Part A: AZD4956 + saruparib (Dose escalation)

    Participants will receive AZD4956 at ascending dose levels in combination with saruparib.

    Drug: AZD4956 · Drug: Saruparib

  • Experimental
    Module 2 Part A Optional PD backfill cohort: AZD4956 + saruparib

    Participants will receive AZD4956 in combination with saruparib.

    Drug: AZD4956 · Drug: Saruparib

  • Experimental
    Module 2 Part A Optional PD backfill cohort: Saruparib monotherapy

    Participants will receive saruparib monotherapy.

    Drug: Saruparib

  • Experimental
    Module 2 Part A Optional non-PD backfill cohort: AZD4956 + saruparib

    Participants with metastatic castrate resistant prostate cancer (mCRPC) will receive AZD4956 in combination with saruparib.

    Drug: AZD4956 · Drug: Saruparib

  • Experimental
    Module 2 Part B: AZD4956 + saruparib (Dose expansion)

    Participants will receive AZD4956 in combination with saruparib.

    Drug: AZD4956 · Drug: Saruparib

Interventions

  • DrugAZD4956

    AZD4956 will be administered orally.

  • Saruparib will be administered orally.

06

What researchers measure

Primary outcomes

  1. Parts A and B: Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    To assess the safety and tolerability of AZD4956 monotherapy and in combination with anti-cancer agent(s).

    Time frame: From Screening (Day -28) to follow-up (up to 3.5 years)

  2. Part B: Progression free survival (PFS)

    PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participants withdraw from study treatment or receive another anti-cancer therapy prior to progression.

    Time frame: Up to 3.5 years

  3. Part A - Number of participants with dose-limiting toxicities (DLTs)

    To assess the safety and tolerability of AZD4956 monotherapy and in combination with anti-cancer agent(s).

    Time frame: Up to 28 days

Secondary outcomes

  1. Objective response (OR)

    OR is defined as if a participant achieves a best overall response (BOR) of confirmed complete response (CR) or partial response (PR), as assessed by the investigator, according to response evaluation criteria in solid tumours (RECIST) v1.1 criterion.

    Time frame: Up to 3.5 years

  2. Duration of response (DoR)

    DoR is defined as the time from the date of first documented OR assessed by RECIST v1.1, in the absence of progression on bone scan assessed by prostate cancer working group 3 (PCWG3), until the date of documented disease progression or death in the absence of disease progression.

    Time frame: Up to 3.5 years

  3. Best Overall Response (BOR)

    To assess the preliminary anti-tumour activity of AZD4956 monotherapy and in combination with anti-cancer agent(s).

    Time frame: Up to 3.5 years

  4. Time to response (TTR)

    TTR is defined as the time from the date of first dose of study intervention until the date of first documented OR assessed by RECIST v1.1, in the absence of progression on bone scan assessed by PCWG3, which is subsequently confirmed.

    Time frame: Up to 3.5 years

  5. Disease control (DC)

    DC is defined as if a participant has achieved a best OR of confirmed CR or PR or SD as BOR assessed by RECIST v1.1, in the absence of progression on bone scan assessed by PCWG3.

    Time frame: Up to 3.5 years

  6. Clinical benefit rate (CBR)

    CBR is defined as the percentage of advanced cancer participants who achieve CR, PR, or at least 16 weeks/24 weeks of stable disease, assessed by RECIST v1.1, in the absence of progression on bone scan assessed by PCWG3, as a result of therapy.

    Time frame: Up to 3.5 years

  7. Part A: Progression free survival (PFS)

    PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participants withdraw from study treatment or receive another anti-cancer therapy prior to progression.

    Time frame: Up to 3.5 years

  8. Percentage change from baseline in tumour size

    The best percentage change from baseline in target lesion (TL) tumour size is the largest decrease (or smallest increase) from baseline for a participant, using RECIST v1.1 assessments.

    Time frame: Up to 3.5 years

  9. Number of participants with cancer antigen 125 (CA125) response (for ovarian cancer participants)

    CA125 response is defined as if at least a 50% reduction in CA125 levels from a pre-treatment sample.

    Time frame: From baseline up to 3.5 years

  10. Radiological progression free survival (rPFS) (for prostate cancer participants)

    PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participants withdraw from study treatment or receive another anti-cancer therapy prior to progression.

    Time frame: Up to 3.5 years

  11. Change from baseline in prostate specific antigen 50 (PSA50) response rate (for prostate cancer participants)

    PSA50 response is defined as if a ≥ 50% decrease in PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later has been achieved.

    Time frame: From baseline up to 3.5 years

  12. Change from baseline in PSA90 response rate (for prostate cancer participants)

    PSA90 response is defined as if a ≥ 90% decrease in PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later has been achieved.

    Time frame: From baseline up to 3.5 years

  13. Change from baseline in PSA undetectable rate

    Undetectable PSA is defined as a measurement of \< 0.2 ng/mL.

    Time frame: At 3, 6 and 9 months

  14. Time to PSA50/90 response (for prostate cancer participants)

    Time to PSA50/90 response is defined as the time from the date of first dose of study intervention until the date of first documented PSA response (≥ 50%/90% decrease in PSA from baseline) that is confirmed by a second consecutive PSA assessment at least 3 weeks later.

    Time frame: Up to 3.5 years

  15. Time to PSA progression (for prostate cancer participants)

    Time to PSA progression is defined as the time from date of first dose of study intervention until the date of first documented PSA progression or the last PSA result in the absence of progression.

    Time frame: Up to 3.5 years

  16. PSA PFS at 6 months (PSA-6)

    PSA progression is defined as an increase in PSA of ≥ 25% from the nadir and an absolute increase of at least 2 ng/mL above nadir beyond 12 weeks. To assess the preliminary anti-tumour activity of AZD4956 monotherapy and in combination with anti-cancer. agent(s)

    Time frame: At 6 months

  17. Area under the concentration-time curve (AUC)

    To characterise the pharmacokinetics (PK) of AZD4956 when given orally as monotherapy and in combination with anti-cancer agent(s).

    Time frame: From date of first dose of study intervention up to 59 days after first dose

  18. Maximum concentration (Cmax)

    To characterise the pharmacokinetics (PK) of AZD4956 when given orally as monotherapy and in combination with anti-cancer agent(s).

    Time frame: From date of first dose of study intervention up to 59 days after first dose

  19. Time to maximum concentration (Tmax)

    To characterise the pharmacokinetics (PK) of AZD4956 when given orally as monotherapy and in combination with anti-cancer agent(s).

    Time frame: From date of first dose of study intervention up to 59 days after first dose

  20. Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 (fe(t1-t2))

    To characterise the pharmacokinetics (PK) of AZD4956 when given orally as monotherapy and in combination with anti-cancer agent(s).

    Time frame: From date of first dose of study intervention up to 16 days after first dose

  21. Renal clearance (CLR)

    To characterise the pharmacokinetics (PK) of AZD4956 when given orally as monotherapy and in combination with anti-cancer agent(s).

    Time frame: From date of first dose of study intervention up to 16 days after first dose

  22. Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 (Ae(t1-t2))

    To characterise the pharmacokinetics (PK) of AZD4956 when given orally as monotherapy and in combination with anti-cancer agent(s).

    Time frame: From date of first dose of study intervention up to 16 days after first dose

  23. Change in amount of KRAB-associated protein-1 phosphorylated on serine 824 [pKAP1 (Ser824)] biomarker in tumour cells at baseline and during treatment

    To evaluate PD of AZD4956 in tumour cells when given orally as monotherapy and in combination with anti-cancer agent(s).

    Time frame: From Baseline up to 3.5 years

07

Study locations

14 of 19 sites recruiting
  • Research Site
    New York, New York 10065, United States
    Recruiting
  • Research Site
    Providence, Rhode Island 02903, United States
    Recruiting
  • Research Site
    Houston, Texas 77030, United States
    Recruiting
  • Research Site
    Fairfax, Virginia 22031, United States
    Recruiting
  • Research Site
    Melbourne, 3000, Australia
    Recruiting
  • Research Site
    Westmead, 2145, Australia
    Recruiting
  • Research Site
    Chūōku, 104-0045, Japan
    Recruiting
  • Research Site
    Kashiwa, 277-8577, Japan
    Recruiting
  • Research Site
    Seoul, 03080, South Korea
    Recruiting
  • Research Site
    Seoul, 120-752, South Korea
    Recruiting
  • Research Site
    Barcelona, 08023, Spain
    Recruiting
  • Research Site
    Barcelona, 08036, Spain
    Recruiting
  • Research Site
    Barcelona, 8035, Spain
    Not yet recruiting
  • Research Site
    Logroño, 26006, Spain
    Not yet recruiting
  • Research Site
    Pozuelo de Alarcón, 28223, Spain
    Not yet recruiting
  • Research Site
    Seville, 41013, Spain
    Not yet recruiting
  • Research Site
    Cambridge, CB2 0QQ, United Kingdom
    Recruiting
  • Research Site
    London, SE1 9RT, United Kingdom
    Not yet recruiting
  • Research Site
    Sutton, SM25PT, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Mar 2030, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 3, 2026
StartActual
Mar 17, 2026
Primary completionEst.
Mar 29, 2030
CompletionEst.
Mar 29, 2030
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites changed recruiting status (7 now recruiting)
Show 7 sites
  • Research Site · Providence, United StatesNot yet recruiting→Recruiting
  • Research Site · Chūōku, JapanNot yet recruiting→Recruiting
  • Research Site · Seoul, South KoreaNot yet recruiting→Recruiting
  • Research Site · Cambridge, United KingdomNot yet recruiting→Recruiting
  • Research Site · Sutton, United KingdomNot yet recruiting→Recruiting
  • Research Site · Westmead, AustraliaNot yet recruiting→Recruiting
  • Research Site · Barcelona, SpainNot yet recruiting→Recruiting
across 2 updates, Oct 1, 2026 – Oct 27, 2026
Show all 2 updates
  1. Oct 27, 2026
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Research Site · Westmead, AustraliaNot yet recruiting→Recruiting
    • Research Site · Barcelona, SpainNot yet recruiting→Recruiting
    • Research Site · Barcelona, SpainNot yet recruiting→Recruiting
    + 2 other changes: identifiers and verification date
  2. Oct 1, 2026
    6 sites changed recruiting status (6 now recruiting)
    Show 6 sites
    • Research Site · Providence, United StatesNot yet recruiting→Recruiting
    • Research Site · Chūōku, JapanNot yet recruiting→Recruiting
    • Research Site · Seoul, South KoreaNot yet recruiting→Recruiting
    • Research Site · Seoul, South KoreaNot yet recruiting→Recruiting
    • Research Site · Cambridge, United KingdomNot yet recruiting→Recruiting
    • Research Site · Sutton, United KingdomNot yet recruiting→Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07446855
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Mar 17, 2026
Primary completion
Mar 29, 2030 (estimated)
Completion
Mar 29, 2030 (estimated)
Last update
Oct 27, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD5305

Start the discussion